CONSHOHOCKEN, PA -- (Marketwire) -- 09/30/10 -- NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announces that Jerry McLaughlin, Vice President of Commercial Operations, will present a brief company overview at the Safeguard Scientifics, Inc. (NYSE: SFE) Investor Day 2010 event on Tuesday, October 5, 2010. The investor day is being held at The Yale Club in New York.
A live audio webcast of the presentation will be available at www.safeguard.com/InvestorDay2010. Please log on approximately 10 minutes prior to the scheduled start time.
NuPathe Inc. is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe's most advanced product candidate, Zelrix, is a transdermal patch for the treatment of migraine. Zelrix actively delivers sumatriptan, the most widely prescribed migraine medication, through the skin in a controlled manner using its proprietary SmartRelief technology.
In addition, NuPathe has two other proprietary product candidates in preclinical development that address large market opportunities: NP201 for the continuous symptomatic treatment of Parkinson's disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder. For more information, please visit NuPathe's website at www.nupathe.com.
Keith A. Goldan
Vice President and Chief Financial Officer
Westwicke Partners, LLC
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here